HUNGARY – Ceva Animal Health, the fifth-largest global animal health company, has announced a major investment in expanding its vaccine manufacturing capabilities with the construction of a state-of-the-art facility in Monor, Hungary.
The 7,000 m² plant, expected to begin operations by the end of 2026, will use advanced technologies to produce fermentation-based multicomponent inactivated vaccines for animals.
This new facility expands the capacity of Ceva Phylaxia, a historic campus with over a century of expertise in combating major livestock diseases through innovative research and vaccine development.
Chairman and CEO Marc Prikazsky described the project as a critical milestone for Ceva, highlighting its commitment to advancing preventive medicine and supporting farmers worldwide with tailored solutions to emerging diseases.
“This project reflects our ambition to build a promising future for our company, employees, and partners while strengthening our research and development capabilities,” Prikazsky noted.
With this facility, Ceva aims to produce over 8 billion vaccine doses annually, reinforcing its position as the most innovative player in vaccine technologies. The company is a leader in vector vaccines for poultry and the first to develop an animal mRNA platform.
For over two decades, Ceva has championed prevention through vaccination, heavily investing in preventive medicine to improve the health of husbandries significantly and fight zoonotic and emerging diseases, contributing to preparing for future pandemics.
Today, 54% of Ceva’s R&D budget is dedicated to vaccine development, and the company already provides more than 50 vaccines to fight 19 zoonotic diseases.
This investment aligns with the rapidly growing global livestock vaccine market, which is expected to expand from US$6.01 billion in 2024 to US$9.80 billion by 2032 at a CAGR of 6.3%.
Ceva’s focus on sustainability and preparedness for zoonotic and emerging diseases underscores its role in addressing future pandemics.
In addition to its manufacturing expansion, Ceva announced the appointment of Christophe Bailet as its new Group Chief Financial Officer. Bailet, who brings extensive international financial experience, succeeds Alain de Woillemont, who held the position for a decade.
Bailet will oversee Ceva’s next refinancing cycle, ensuring the company’s ambitious growth plans are met.
He emphasised the opportunity to contribute to Ceva’s innovation leadership and mission to address industry challenges.
Sign up HERE to receive our email newsletters with the latest news updates and insights from Africa and the World and follow us on our WhatsApp channel for updates.
